NCT06202781

Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

Using Single-cell Sequencing to Explore Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 28 (estimated)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to analyze the tumor microenvironment (TME) in gastric cancer patients treated with combined immunotherapy and chemotherapy. The main questions it aims to answer are: * Provide profiles of TME between pre-treatment and post-treatment to gain insights into the mechanisms of immunotherapy combined with chemotherapy in advanced gastric cancer * Investigate the crucial factors affecting treatment efficacy by comparing gastric cancer patients with varying treatment responses

Conditions

• Gastric Cancer
• Tumor Microenvironment
• Immunotherapy
• Chemotherapy

Interventions

Type	Name	Description
DRUG	SOX plus PD-1 inhibitor	S-1, Oxaliplatin and nivolumab/sintilimab
PROCEDURE	Gastroscopic biopsy	Gastroscopy and biopsy

Timeline

• Start date: 2022-07-01
• Primary completion: 2024-06-30
• Completion: 2024-07-31
• First posted: 2024-01-12
• Last updated: 2024-01-12

Locations

1 site across 1 country: China